Lu Chun-Li, Zheng Ruo-Xiang, Xue Xue, Zhang Xiao-Wen, Liu Xue-Han, Jin Xin-Yan, Pu Feng-Lan, Lan Hui-Di, Fang Min, Kong Ling-Yao, Willcox Merlin, Graz Bertrand, Houriet Joelle, Hu Xiao-Yang, Liu Jian-Ping
Centre for Evidence-Based Chinese Medicine, Beijing University of Chinese Medicine, Beijing, China.
First Clinical College and affiliated hospital, Hubei University of Traditional Chinese Medicine, Wuhan, China.
Integr Med Res. 2021;10(Suppl):100798. doi: 10.1016/j.imr.2021.100798. Epub 2021 Oct 19.
We aimed to investigate use of infection control behaviours, preventative and therapeutic interventions, and outcomes among respondents to an online survey during the COVID-19 pandemic in China.
The survey was designed by an international team, translated and adapted to simplified Chinese, including 132 kinds of traditional Chinese medicine (TCM) preparation recommended by guidelines. It was distributed and collected from February to May 2021, with data analysed by WPS spreadsheet and Descriptive statistics were used to describe demographics and clinical characteristics, diagnosis, treatments, preventative behaviours and interventions, and their associated outcomes.
The survey was accessed 503 times with 341 (67.8%) completions covering 23 provinces and four municipalities in China. Most (282/341, 82.7%) respondents reported no symptoms during the pandemic and the majority (290/341, 85.0%) reported having a SARS-CoV-2 PCR test at some point. Forty-five (13.2%) reported having a respiratory infection, among which 19 (42.2%) took one or more categories of modern medicine, e.g. painkillers, antibiotics; 16 (35.6%) used TCM interventions(s); while seven respondents combined TCM with modern medicine. All respondents reported using at least one behavioural or medical approach to prevention, with 22.3% taking TCM and 5.3% taking modern medicines. No respondents reported having a critical condition related to COVID-19.
We found evidence of widespread use of infection control behaviours, modern medicines and TCM for treatment and prevention of COVID-19 and other respiratory symptoms. Larger scale studies are warranted, including a more representative sample exploring TCM preparations recommended in clinical guidelines.
我们旨在调查中国新冠疫情期间在线调查受访者的感染控制行为、预防和治疗干预措施及其结果。
该调查由一个国际团队设计,翻译成简体中文并进行了调整,包括指南推荐的132种中药制剂。于2021年2月至5月进行发放和收集,数据通过WPS电子表格进行分析,使用描述性统计来描述人口统计学和临床特征、诊断、治疗、预防行为和干预措施及其相关结果。
该调查被访问503次,341人(67.8%)完成,覆盖中国23个省和4个直辖市。大多数(282/341,82.7%)受访者在疫情期间没有症状,大多数(290/341,85.0%)受访者表示在某个时间点进行过新冠病毒PCR检测。45人(13.2%)报告有呼吸道感染,其中19人(42.2%)服用了一种或多种现代药物,如止痛药、抗生素;16人(35.6%)使用了中医干预措施;7名受访者将中医和现代医学结合使用。所有受访者都报告至少使用了一种行为或医学预防方法,22.3%的人服用中药制剂,5.3%的人服用现代药物。没有受访者报告有与新冠相关的危急情况。
我们发现有证据表明,感染控制行为、现代药物和中药制剂被广泛用于治疗和预防新冠及其他呼吸道症状。有必要开展更大规模的研究,包括采用更具代表性的样本,探索临床指南中推荐的中药制剂。